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The Kaposi’s Sarcoma-Associated Herpesvirus ORF34 Protein Binds to
HIF-1␣ and Causes Its Degradation via the Proteasome Pathway
Muzammel Haque, Konstantin G. Kousoulas
Division of Biotechnology and Molecular Medicine and Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge,
Louisiana, USA

Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent for Kaposi’s sarcoma (KS) and two other lymphoproliferative disorders, primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD). Kaposi’s sarcoma is a highly
vascular tumor, and recently both hypoxia-inducible factor 1␣ (HIF-1␣) and HIF-2␣ were detected in KS samples, indicating a
role of HIFs in the KSHV life cycle. Previously, we showed that ORF34, a lytic gene of unassigned function, was activated by hypoxia and that ORF34 transcription was upregulated by both HIFs (M. Haque, D. A. Davis, V. Wang, I. Widmer, and R. Yarchoan,
J Virol. 77:6761– 6768, 2003). In the present study, we show that coexpression of ORF34 with HIF-1␣m (degradation-resistant
HIF-1␣) caused substantial reduction in HIF-1␣-dependent transcription, as evidenced by reporter assays. Two-way immunoprecipitation experiments revealed that ORF34 physically interacted with HIF-1␣m in transient expression experiments. Deletion analysis revealed that three different ORF34 domains interacted with the amino-terminal domain of HIF-1␣. Also, purified
HIF-1␣ and ORF34 proteins interacted with each other. The observed transcriptional inhibition of HIF-1␣-dependent promoters was attributed to degradation of HIF-1␣ after binding with ORF34, since the overall amount of wild-type HIF-1␣ but not the
degradation-resistant one (HIF-1␣m) was reduced in the presence of ORF34. Moreover, ORF34 caused degradation of HIF-1␣ in
a dose-dependent manner. Inhibition of the ubiquitin-dependent pathway by the chemical proteasome inhibitor MG132 prevented HIF-1␣ degradation in the presence of ORF34. These results show that ORF34 binds to HIF-1␣, leading to its degradation
via the proteasome-dependent pathway.

K

aposi’s sarcoma-associated herpesvirus (KSHV), also known
as human herpesvirus 8 (HHV-8), is a gamma-2 herpesvirus
that is related to Epstein-Barr virus (EBV) and herpesvirus saimiri
(1, 2). KSHV is the causative agent for Kaposi’s sarcoma (KS) and
two other lymphoproliferative disorders, primary effusion lymphoma (PEL) and multicentric Castleman’s disease (3–5).
KSHV shares significant sequence homology with EBV (6). As
with other herpesviruses, KSHV has two distinct phases of life
cycles, latent and lytic replication. During latency, a limited number of viral genes are expressed that play a key role in the replication and maintenance of the viral genome in KSHV-infected cells
(7–9).
Lytic gene expression can be induced by treatment of latently
infected cells with chemical agents, such as 12-0-tetradecanoyl
13-acetate (TPA) and sodium butyrate (10, 11). Recently, it has
been reported that hypoxia, a physiologic stimulus, can also induce lytic replication of KSHV in PEL cells (12). The term “hypoxia” refers to the presence of low (inadequate) levels of oxygen in
cells or tissues. This condition represents a physiological stress
that allows KSHV to replicate and cause tumors in human body
extremities, where oxygen levels typically are low. Recent results
from different laboratories indicated that hypoxia and hypoxiainducible factors (HIFs) play important roles in the KSHV life
cycles (13–18).
HIFs are heterodimeric transcription factors composed of one
of the three oxygen-sensitive HIF-␣ subunits (HIF-1␣, HIF-2␣,
and HIF-3␣) and a constitutively expressed HIF-1␤ subunit, also
known as aryl hydrocarbon receptor nuclear translocator (ARNT)
(19–23). Under normoxic conditions, HIF-␣ proteins are expressed but targeted for proteasomal degradation by interaction
with von Hippel-Lindau (pVHL) tumor suppressor protein and
subsequent polyubiquitination (24–27). The interaction of pVHL
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and HIF-␣ proteins is regulated by the hydroxylation of specific
proline residues in the oxygen-dependent degradation domain
(ODD) of HIF-␣ (28–30). In mammalian cells, three prolyl hydroxylase domain (PHD) enzymes, PHD1, PHD2, and PHD3,
also known as HIF prolyl hydroxylases (HPHs), have been shown
to hydroxylate HIF-␣ proteins (31–33). In the presence of oxygen,
the activity of HIF-␣ proteins is also regulated by hydroxylation of
specific asparagine residues within the C-terminal transactivation
domain of HIF-␣ by a specific asparaginyl hydroxylase, called factor inhibiting HIF (FIH) (34–36). Under hypoxic conditions,
PHD activity is limited, which increases the stability of HIF-␣
proteins, leading to rapid accumulation of the protein and an
increased ability to recruit coactivators (37, 38). These enzymatic
modifications can also be inhibited by iron chelation and cobalt
ions (38). Once stabilized, HIF-␣ proteins translocate to the nucleus, heterodimerize with constitutively expressed HIF-␤ subunit, bind to hypoxia-responsive elements (HREs) within the promoter or enhancer region of hypoxia-responsive target genes, and
upregulate gene expression (39). The core consensus sequence
that HIF heterodimers bind to has been identified as 5=-R (A/G)
CGTG-3= (40). HIF-1␣ and HIF-2␣ have a high degree of sequence
similarity and biochemical properties (19). Both proteins dimerize
with ARNT and bind to the same DNA sequences but have distinct
biological functions (41, 42). Less is known about HIF-3␣ compared
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to HIF-1␣ and HIF-2␣. While HIF-1␣ and HIF-2␣ act as transcriptional activators for their target genes, HIF-3␣ has been shown to act
as a transcriptional repressor (39).
In KSHV, there is increasing evidence that hypoxia and HIFs
play an important role in KSHV latent and lytic replication. Kaposi’s sarcoma is a highly vascular tumor, and recently both
HIF-1␣ and HIF-2␣ were detected in KS samples, indicating a role
of HIFs in the KSHV life cycle (14, 43). It was recently reported
that two KSHV latent proteins, latency-associated nuclear antigen
1 (LANA1) and viral interferon regulatory factor 3 (VIRF3), also
known as LANA2, stabilize HIF-1␣ through protein-protein interactions (13, 17). Latent KSHV infection of endothelial cells increases the level of both HIF-␣ mRNA and protein (14). More
recently, hypoxia and HIFs have been shown to induce transcription of LANA in KSHV-infected PEL cells, and the LANA promoter can be transcriptionally activated by both HIF-␣ proteins
acting through at least one HIF binding site within the promoter
region (44). The viral G protein-coupled receptor (vGPCR) carried by ORF74 is a KSHV lytic gene shown to upregulate vascular
endothelial growth factor (VEGF) production by stimulating the
activity of HIF-1␣ (18). Moreover, both HIF-␣ proteins can induce transcription and expression of the KSHV RTA (15), and
several HIF binding sites have been identified in the promoter
region of RTA (13).
We have reported that ORF34, a lytic gene of unknown function, was activated by hypoxia. Moreover, both HIFs upregulated
ORF34 transcription through an HRE located in the ORF34 promoter region (15). In addition, we demonstrated that the same
ORF34P HRE could upregulate transcription of downstream
genes carried by ORF35 to ORF37 (16). In the present study, we
have investigated functional interactions between ORF34 and
HIF-1␣ and identified ORF34 as the interacting partner of HIF1␣. Our data demonstrate that ORF34 promotes degradation of
HIF-1␣ acting through the ubiquitin proteasome pathway.
MATERIALS AND METHODS
Cell culture and transfection. Human embryonic kidney 293 (HEK293)
and 293T (HEK293T) cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum and 1% antibiotics.
The cells were maintained at 37°C in a 5% CO2 and 95% air incubator. For
immunoprecipitation and immunoblotting, subconfluent cells were
transfected in 10-cm or 6-well plates. For luciferase assay, cells were transfected in 24-well plates. All transfections were carried out using Genjet in
vitro transfection reagent from SignaGen Laboratories (Ijamsville, MD) as
recommended by the manufacturer.
Expression plasmids. Full-length ORF34 was amplified by PCR with
specific primers containing BglII and EcoRI from BCBL-1 genomic DNA
and cloned into green fluorescent protein (GFP)-tagged pEGFP-C1
(Clontech, CA) in the same sites. Different deletion mutants of GFP34
were constructed with specific primers containing BglII and SalI sites
using GFP34 as the template. The specific sites of different deletions are
shown schematically in Fig. 3A.
Full-length wild-type human HIF-1␣ (pHA HIF-1␣W) and its mutant
plasmid containing two alanine substitutions in place of proline at positions P402A and P564A (pHA HIF-1␣m), which escape pVHL-mediated
degradation, were provided by Eric Huang (University of Utah School of
Medicine, Salt Lake City, UT). These plasmids were used as templates in
PCR to construct full-length Flag-tagged wild-type and degradation-resistant HIF-1␣ using gene-specific primers. These gene constructs were
subsequently inserted into HindIII-XbaI sites of p3XFLAG-CMV14 expression vector (Sigma, MO) and designated Flag-tagged HIF-1␣w and
Flag-tagged HIF-1␣m. To construct mammalian glutathione S-trans-
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ferase (GST)-fused expression vectors encoding full-length HIF-1␣m and
its different deletion mutants, the full length and specific segments of
HIF-1␣ were subcloned into the KpnI-NotI sites of a pEBG expression
vector (plasmid 22227; Addgene, MA) using Flag-tagged HIF-1␣m as a
PCR template. The specific sites of different deletions are shown schematically in Fig. 4A. Hemagglutinin (HA)-tagged ubiquitin expression plasmid was a gift from Clinton Jones (University of Nebraska, Lincoln, NE).
For prokaryotic expression, full-length ORF34 and HIF-1␣ were
cloned into the EcoRI-XhoI site of pGEX4T-1 (GE Healthcare, NJ) and
the BamHI-NotI site of pET-32a (EMD Millipore, MA) expression vector,
respectively.
Reporter plasmids. The wild-type human erythropoietin (EPO)
HRE-luciferase reporter (pEpoE-luc) containing a 50-bp EPO 3= enhancer sequence, as well as its mutant (pEpoEm-luc), containing a 3-bp
substitution in the HIF-␣ binding site (45), were obtained from Eric
Huang (University of Utah School of Medicine, Salt Lake City, UT). The
human VEGFp12 reporter (46) was constructed by inserting a 99-bp fragment containing the HIF-␣ binding site upstream of the simian virus 40
(SV40) promoter of the pGL3 promoter vector into NheI-BglII sites using
primers VEGFp12 F (5=-CGA GCT AGC CCT TTG GGT TTT GCC AGA3=) and VEGF p12 R (5=-AGC AGA TCT ACG GGA AGC TGT GTG
GTT-3=; boldface letters indicate restriction endonuclease sites).
Antibodies and inhibitors. Rabbit polyclonal and mouse monoclonal
antibodies against GFP (A01388 and A00185) and monoclonal antibody
to GST (A00865) were purchased from GenScript (Piscataway, NJ).
Mouse monoclonal anti-FLAG M2 (F3165) and anti-␤-actin (A5316)
were from Sigma (St. Louis, MO). Rabbit polyclonal antibody to GST
(SC-459) and mouse monoclonal antibody to HA (SC-7392) were from
Santa Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal antibody to anti-FLAG M2 (200472) was from Agilent Technologies, Inc.
(Wilmington, DE). Mouse monoclonal anti-human HIF-1␣ (610959)
was from BD Biosciences (San Jose, CA). For secondary antibodies, where
appropriate, blots were incubated with either alkaline phosphatase-conjugated goat anti-mouse (S3721) and goat anti-rabbit (S3721) antibodies
(Promega, WI) or horseradish peroxidase (HRP)-conjugated goat antimouse IgG (SC-2005) from Santa Cruz Biotechnology. The proteasome,
lysosome, and protein synthesis inhibitors MG132 (C2211), chloroquine
(CQ), and cycloheximide, respectively, were from Sigma.
Transfection and reporter assay. The day before transfection,
HEK293 cells were plated at 60 to 70% confluence in a 24-well plate and
transfected with 250 ng each of VEGFp12, pEpoE-luc, and pEpoEm-luc
promoters along with 125 ng of Flag-tagged HIF-1␣w or Flag-tagged HIF1␣m plasmid in the presence or absence of 125 ng of GFP34 expression
plasmid. Cells were also transfected with 2 ng/well of an internal control
plasmid, Renilla luciferase (pRL-SV40), to normalize transfection efficiency, and the total amount of DNA was kept constant by using the
appropriate control vector. After transfection, cells were incubated in normoxic conditions for 30 h and lysed using passive lysis buffer. Firefly and
Renilla luciferase activities were measured with a Victor-2 luminometer
(PerkinElmer, MA) using a dual-luciferase kit (Promega, WI) and were
normalized to an internal control plasmid. Luciferase activity was calculated by dividing the activity for each reporter by that of the empty vector
and compared to the results obtained for HIF-1␣ or the combination of
HIF-1␣ and GFP34.
Immunoblot analysis. Cell lysates were prepared in 0.5% IGEPAL
lysis buffer (50 mM Tris-HCl, pH 8.00, 150 mM NaCl, 0.5% IGEPAL
CA-630, 1 mM EDTA) supplemented with protease inhibitor and clarified by centrifugation for 10 min at 4°C. Cleared lysates were mixed with
sample buffer, heated at 92°C for 5 min, and electrophoretically separated
through 4 to 20% Tris-HEPES-SDS gels (Thermo Scientific, IL). Following electrophoresis, gels were transferred to nitrocellulose membranes
using an iBlot dry transfer device (Invitrogen, CA) and blocked for 60 min
in Tris-buffered saline containing 0.1% Tween 20 (TBST) plus 5% nonfat
dry milk. Membranes were probed with the specific primary antibodies
and then with either goat anti-mouse secondary antibody conjugated with
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alkaline phosphatase or HRP-conjugated goat anti-mouse IgG. After
washing the membranes 3 to 4 times with phosphate-buffered salineTween 20 (PBS-T), the specific signal was detected with appropriate substrate.
Immunoprecipitations. At the indicated times posttransfection, cells
were washed once with PBS and whole-cell extracts were prepared in 0.5%
IGEPAL lysis buffer supplemented with protease inhibitor. Cell extracts
were incubated at 4°C for 10 min on a shaker and centrifuged at 14,000
rpm for 10 min, and supernatants were collected into new tubes. Immunoprecipitation reactions were performed by using protein G Dynabeads
(Invitrogen, CA) or protein A/G-plus-agarose beads (Santa Cruz, CA)
according to the manufacturer’s instructions. Briefly, cell extracts were
incubated with specific antibodies overnight at 4°C. The next day, 20 l of
Dynabeads or protein A/G plus agarose was added to the antigen-antibody complex and incubated at room temperature (RT) for 20 min. After
being washed with PBS-T 3 or 4 times, the samples were eluted in 35 l of
sample buffer heated at 72°C for 10 min, subjected to SDS-PAGE using 4
to 20% Tris-HEPES-SDS gels, and transferred to a nitrocellulose membrane using an iBlot dry transfer device. After blocking the nonspecific
binding sites, the membranes were analyzed by immunoblotting with
specific antibodies as described above. The presence of specific proteins in
transfected cells was confirmed by immunoblotting with specific antibodies to each protein.
Expression and purification of fusion proteins. Full-length HIF-1␣
was expressed from pET-32a expression vector as 6His- and thioredoxin
(trx)-tagged fusion proteins and purified using Bio-Rad’s automated Profanity IMAC (immobilized metal affinity chromatography) column according to the manufacturer’s instructions. Briefly, a single colony of
Escherichia coli BL21 star (DE3) (Invitrogen, CA) harboring the gene was
grown in 2 ml of LB medium at 37°C overnight with appropriate antibiotics on a rotating incubator. The next day, 2 ml of overnight culture was
added to 98 ml of fresh LB medium and grown at 37°C until the optical
density at 600 nm (OD600) of the cultured cells reached 0.6 to 0.8. Expression of the fusion protein was induced with 0.25 mM IPTG (isopropyl-␤D-thiogalactopyranoside) for 3 h at 32°C. The induced bacterial cultures
were harvested, washed once in STE buffer (10 mM Tris-HCl, pH 8.0, 150
mM NaCl, 1 mM EDTA), and treated with 1 mg/ml of lysozyme at RT for
30 min, followed by the addition of 50 U/ml benzonase and incubation at
RT for another 60 min. Bacterial lysates were then pelleted by centrifugation at 4,600 rpm for 15 min and the supernatant discarded. Pellets were
lysed in lysis buffer (10 mM Tris-HCl, pH 8.0, 300 mM NaCl, 10 mM
imidazole) containing 0.25 to 1% N-lauroylsarcosine (Sarkosyl) until the
lysis was completed. Cells were pelleted by centrifugation at 14,000 rpm
for 20 min at 4°C, and supernatant was collected. Triton X-100 was added
to the clear lysate at a final concentration of 3 to 4% and incubated at RT
for 30 min, after which it was subjected to purification by a Profinia
instrument.
Full-length ORF34 was expressed as a GST fusion protein and purified
by binding to glutathione-Sepharose beads using column chromatography. Briefly, E. coli BL21 star (DE3) harboring individual colonies of GST
and GST34 was induced, and cell lysates were prepared as described
above. To each clarified and Triton X-100-treated cell lysate, 500 l of
glutathione Sepharose beads previously washed with PBS-T was added,
and the mixture was incubated for at least 1 h to overnight at 4°C. The
bead-bound protein was loaded into gravity flow columns and washed
extensively with PBS-T. Finally, the protein bound to beads was eluted
with GST elution buffer containing 10 mM reduced glutathione in 50 mM
Tris-HCl, pH 8.0.
In vitro pulldown assays. For pulldown assays, equal amounts of GST
and GST34 proteins were mixed with 250 ng of pET-32a-HIF-1␣ in 0.5 ml
of pull-down buffer (50 mM Tris-HCl, pH 8.00, 150 mM NaCl, 0.5%
IGEPAL CA-630, 1 mM EDTA, 1 mM dithiothreitol [DTT], and 10%
glycerol) and incubated at 4°C for 20 min. Glutathione-Sepharose 4B (15
l) was added to each tube and incubated for an additional 30 min. The
beads were washed extensively with pull-down buffer, and the bound
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FIG 1 ORF34 suppresses the transcriptional activity of VEGF and EPO luciferase reporters mediated by HIF-1␣. Human VEGFp12 (A), an HIF-1-specific
promoter, pEpoE-luc (B), and its mutant, pEpoEm-luc (C), an HIF-2-specific
promoter, were cotransfected into HEK293 cells with 250 ng of each of these
reporters and the indicated amount of Flag-tagged HIF-1␣ wild-type or mutant plasmid in the absence or presence of GFP34. After 30 h of normoxic
incubation, cells were harvested and assayed for luciferase activity. Results
were normalized to cells transfected with empty vector. Statistical analyses
were done using GraphPad Prism 5, and P values (P ⬍ 0.05) of each treatment were compared to the control vector and are indicated where significant.
Each result is the mean from two independent experiments done in triplicate.
EV, empty vector.

proteins were eluted by boiling in 2⫻ sample buffer at 92°C for 5 min. The
eluted proteins were analyzed by SDS-PAGE followed by Western blotting
using antibody to HIF-1␣.
Protein degradation and stability assays. HEK293 cells were
cotransfected with Flag-tagged HIF-1␣w or HIF-1␣m with or without
GFP34 in 6-well plates using 1 g of DNA per well, and the total
amount of DNA was adjusted (where appropriate) using control vector. After 30 h of transfection, cells were washed once with culture
medium and supplemented with 10 M MG132, 100 M chloroquine,
or control dimethyl sulfoxide (DMSO) in specific wells for 16 h and
harvested 46 h posttransfection. For protein stability assays, after 24 h
of transfection cells were treated with 50 g/ml of cycloheximide for
the indicated time periods to block new protein synthesis. Whole-cell
extracts were prepared in 0.5% IGEPAL lysis buffer and immunoblotted with specific antibodies.
In vivo ubiquitination assay. For ubiquitination assays, HEK293 cells
were cotransfected with plasmids encoding GFP34 or Flag-tagged wild
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FIG 2 In vivo and in vitro interaction of ORF34 with HIF-1␣. (A) Schematic diagram showing coding potentials of ORF34 and HIF-1␣ protein along with
different regulatory domains of HIF-1␣. KSHV ORF34 is encoded by 327 amino acids with unknown function, and no functional domains have been identified.
HIF-1␣ protein is 826 amino acids long. It has bHLH and PAS domains at the N terminus, which mediate DNA binding, dimerization, and protein-protein
interactions; an ODD domain at the central region, which regulates the oxygen-dependent stability of HIF-1␣ protein through the hydroxylation of two specific
proline residues, as indicated; and two transactivation domains at the C terminus (N-TAD and C-TAD) that are involved in the transregulatory function of
HIF-1␣ protein. (B and C) In vivo interactions between KSHV ORF34 and human HIF-1␣. Human 293T cells were transiently transfected with GFP34 or
cotransfected with mammalian GST-tagged degradation-resistant HIF-1␣ as indicated. After 30 h of transfection, whole-cell extracts were prepared and
immunoprecipitated (IP) using either anti-GFP (B) or anti-GST (C) antibody. The immunoprecipitates were analyzed by immunoblotting (IB) with anti-GST
or anti-GFP antibody. The presence of GFP34 and GST-HIF-1␣ in the cell extracts was analyzed by immunoblotting with specific antibodies. Arrowheads
indicate specific binding, and an asterisk denotes nonspecific binding by the antibody used. (D) The relative purities of GST, GST34, and pET-32a-HIF-1␣
proteins used in the binding experiment are shown, as evaluated by SDS-PAGE and Coomassie blue staining. (E) In vitro interaction of HIF-1␣ and ORF34 in a
GST pulldown assay. His-tagged purified HIF-1␣ was incubated with equal amounts of purified GST and GST34 protein, subjected to Western blotting, and
probed with anti-HIF-1␣ antibody.

type HIF-1␣ in the presence of HA-ubiquitin or a combination of these
plasmids as shown in Fig. 7. After 30 h of transfection, cells were washed
once with culture medium and supplemented with 10 M MG132 for 16
h before harvest. After 46 h of transfection, cell lysates were prepared in
0.5% IGEPAL lysis buffer, and equal amounts of cell lysates (800 g) were
immunoprecipitated with anti-Flag, anti-HA, or anti-GFP antibody at
4°C overnight. The next day, 20 l of protein A/G plus agarose was added
to the antigen-antibody complex and incubated at 4°C for 60 min. After
washing 3 or 4 times with lysis buffer, the samples were eluted in 30 l of
sample buffer heated at 92°C for 5 min and subjected to SDS-PAGE.
Immunoprecipitates were then analyzed by immunoblotting with specific
antibody as indicated. The presence of each protein in the transfected cell
lysates was analyzed by immunoblotting of equal amounts of total cell
lysates with specific antibody.
Statistical analysis. Statistical analyses were performed using GraphPad Prism 5 software. For comparisons of control reporters under different treatments, data were analyzed using one-way analysis of variance
(ANOVA) followed by Bonferroni’s multiple-comparison test, and P values of less than 0.05 were considered statistically significant.

RESULTS

ORF34 inhibits transcriptional activity of HIF-1␣. KSHV
ORF34 is an early-late gene encoding 327 amino acids with unassigned function (6). ORF34 is the first viral gene, not only for
KSHV but also among all viral genes, shown to be activated by
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hypoxia (15). Previously, we showed that both HIF-1␣ and
HIF-2␣ strongly upregulated the ORF34 promoter acting through
a functional HRE in the promoter region of ORF34 (15, 16). In the
present study, we investigated whether transcriptional activity of
HIF-1␣ is affected by ORF34. We selected two prototypic HIF-␣responsive promoters. VEGFp12 is an HIF-1␣-specific (46) luciferase reporter which contains one copy of an HIF-␣ binding site
inserted upstream of an SV40 promoter (pGL3 promoter; Promega). The EPO HRE luciferase reporter is an HIF-2␣-specific
promoter (47, 48) containing a 50-bp EPO 3= enhancer sequence
inserted upstream of the SV40 promoter (45). HEK293 cells were
cotransfected with VEGFp12 or with wild-type pEpoE-luc HRE
luciferase reporter plasmid along with Flag-tagged HIF-1␣w or
HIF-1␣m alone or in combination with GFP34 and Flag-tagged
HIF-1␣m (Fig. 1A and B). These experiments revealed that both
wild-type VEGFp12 and pEpoE-luc promoters were moderately
activated by Flag-tagged HIF-1␣w plasmids, and this activation
was further enhanced in cells cotransfected with Flag-tagged HIF1␣m-expressing plasmids. However, coexpression of GFP34 substantially decreased the transcriptional activity of HIF-1␣ for both
reporting promoters. In cells transfected with the mutant
pEpoEm-luc reporter, the luciferase activity was not affected by
either Flag-tagged HIF-1␣w or Flag-tagged HIF-1␣m alone or in
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combination with GFP34 (Fig. 1C). These results indicate that
ORF34 acts as a negative regulator of HIF-1␣.
Interaction of ORF34 and HIF-1␣ protein. Based on the results that ORF34 expression caused substantial reduction in
HIF-1␣-dependent transcriptional activation, we tested whether
HIF-1␣ physically interacted with ORF34 protein in transient coexpression experiments. The full-length coding sequences of
ORF34 and HIF-1␣ were cloned into GFP- and GST-tagged expression vectors (Fig. 2A). For coimmunoprecipitation experiments, 293T cells were transfected with GFP34 alone or in the
presence of GST-HIF-1␣m, a plasmid with specific proline mutations at the ODD domain of HIF-1␣ (Fig. 2A) that causes resistance to pVHL-mediated degradation while remaining functional
in normoxia (25, 28). Cell lysates from transfected cells were first
immunoprecipitated with anti-GFP polyclonal antibody and then
immunoblotted with anti-GST monoclonal antibody to detect the
presence of GST-HIF-1␣ bound to GFP34. The anti-GFP antibody coimmunoprecipitated GST-HIF-1␣ from the cell extract
obtained from cells cotransfected with GST-HIF-1␣m plasmid
but not from the cell lysates transfected with control vector
(Fig. 2B). In the reverse experiment, anti-GST polyclonal antibody coimmunoprecipitated GFP34 only in the presence of GSTHIF-1␣m but not from control cell lysates (Fig. 2C). The presence
of GFP34 and GST-HIF-1␣ in the cell extracts was detected with
specific antibodies, and actin was used to monitor the equal loading control (Fig. 2B and C).
To confirm this interaction in a cell-free system, we performed
an in vitro GST pulldown experiment using purified, full-length
GST34 and pET-32a-HIF-1␣ proteins expressed in E. coli
(Fig. 2D). Specifically, purified GST and GST34 proteins were
incubated directly with pET-32a-HIF-1␣ in a pulldown buffer (50
mM Tris-HCl, pH 8.00, 150 mM NaCl, 0.5% IGEPAL CA-630, 1
mM EDTA, 1 mM DTT, and 10% glycerol) as described in Materials and Methods. HIF-1␣ bound specifically to GST34 but not to
control GST protein (Fig. 2E). Collectively, these results demonstrate that KSHV ORF34 interacts with HIF-1␣ in vivo and in vitro.
Identification of interacting domains of HIF-1␣ and ORF34
proteins. In order to identify the specific interacting regions of
ORF34 for HIF-1␣, we constructed different deletion mutants of
the ORF34 gene (Fig. 3A). GFP34 D1, D2, and D3 appeared to be
expressed in the cytoplasm of transfected cells (not shown). We
have tested the ability of each ORF34 domain to bind to HIF-1␣
after coexpression in HEK293 cells using coimmunoprecipitation
experiments (Fig. 3B). The three GFP34 deletion mutants were
cotransfected with full-length Flag-tagged HIF-1␣m plasmid (Fig.
3B). Cell extracts were immunoprecipitated with anti-GFP polyclonal antibody, and the immunoprecipitates were probed with
anti-HIF-1␣ antibody to detect the regions of ORF34 bound to
HIF-1␣. Results showed that the C terminus of ORF34 (GFP34
D3), which encompass the amino acids 217 to 327 of ORF34,
bound strongly to HIF-1␣, whereas GFP34 D1 and D2 bound
weakly to HIF-1␣ (Fig. 3B).
To identify the binding domains of HIF-1␣ to ORF34, different deletion mutants of HIF-1␣ were constructed using a mammalian GST-tagged vector (Fig. 4A). The predicted size of HIF-1␣
is 93 kDa, and that of GST is 25 kDa. Therefore, the predicted size
of HIF-1␣ fused with GST is 118 kDa. These GST-HIF-1␣ deletion
mutants were cotransfected with GFP34 into HEK293 cells, and
cell extracts were immunoprecipitated with anti-GFP polyclonal
antibody (Fig. 4B). The immunoprecipitates were probed with
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FIG 3 Identification of ORF34 regions that interact with HIF-1␣. (A) Schematic diagram showing the different deletion mutants of ORF34 (D1, D2, and
D3) used in the IP assay. (B) HEK293 cells were transiently transfected with
Flag-tagged HIF-1␣m along with different deletion mutants (DM) of GFP34 as
indicated. After 30 h of transfection, whole-cell extracts were prepared and
immunoprecipitated with anti-GFP antibody. The immunoprecipitates were
analyzed by immunoblotting with anti-HIF-1␣ antibody. The presence of
GFP34 and HIF-1␣ in the whole-cell extracts was analyzed by immunoblotting
using specific antibodies.

anti-GST monoclonal antibody to detect the HIF-1␣ domains
bound to GFP34. Results revealed that bHLH and PAS domains of
HIF-1␣ (GST-bHLH D1 and GST-PAS D2) bind to ORF34
(Fig. 4B).
ORF34 downregulates HIF-1␣ protein levels. Initial experiments in which GFP34 was coexpressed with Flag-tagged HIF1␣m plasmid indicated a potential degradation of HIF-1␣ in the
presence of GFP34 (not shown). To further investigate this phenomenon, HEK293 cells were cotransfected with HIF-1␣w or mutant plasmids in the presence or absence of GFP34 (Fig. 5A). After
30 h of transfection, cell extracts were prepared and the levels of
HIF-1␣ and ORF34 proteins were evaluated by immunoblotting
with specific antibodies. Expression of wild-type HIF-1␣ was
completely inhibited in the presence of ORF34 (Fig. 5A, lanes 2
and 4). Moreover, a reduced level of HIF-1␣ was detected in cells
cotransfected with GFP34 and Flag-tagged HIF-1␣m compared to
cells transfected without the GFP34 expression plasmid (Fig. 5A,
lanes 3 and 5), indicating that ORF34 causes HIF-1␣ degradation.
The observed GFP34-induced degradation of HIF-1␣ occurred in
a dose-dependent manner. Specifically, increasing amounts of
GFP34 tested against a constant amount of Flag-tagged HIF-1␣w
led to a dose-dependent decrease in HIF-1␣ protein levels
(Fig. 5B).
ORF34 promotes the proteasomal degradation of HIF-1␣. In
mammalian cells, two major pathways mediate protein degradation, the ubiquitin-proteasome pathway and the lysosomal degradation pathway. HIF-1␣ protein undergoes proteasomal degradation by interacting with pVHL and many other cellular proteins
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FIG 5 ORF34 reduces the level of HIF-1␣ protein in cotransfected cells. (A)
FIG 4 Identification of HIF-1␣ domains that interact with ORF34. (A) Schematic diagram showing the different deletion mutants of GST-HIF-1␣ (D1,
D2, D3, and D4) used in the IP assay. (B) HEK293 cells were transiently transfected with GFP34 along with different deletion mutants (DM) of GSTHIF-1␣ as indicated. After 30 h of transfection, whole-cell extracts were
prepared and immunoprecipitated using anti-GFP antibody. Immunoprecipitates were analyzed by anti-GST antibody to detect the specific segment of
GST-HIF-1␣ bound to ORF34 protein. Arrowheads indicate specific binding,
and an asterisk denotes nonspecific binding by the antibody used. (C) The
presence of GST-HIF-1␣ and GFP34 in the whole-cell extracts was analyzed by
immunoblotting using specific antibodies. The asterisk in the upper panel
denotes nonspecific binding by the antibody used.

(25, 28–30, 49). In order to understand the degradation pathway
of HIF-1␣ in the presence of ORF34, we used specific inhibitors of
either proteasome- or lysosome-dependent degradation to treat
cells cotransfected with HIF-1␣ and ORF34. HEK293 cells were
cotransfected with GFP34 and Flag-tagged HIF-1␣w and treated
with the specific inhibitors of proteasome- and lysosome-dependent degradation, MG132 (MG) and chloroquine (CQ), respectively. Immunoblot analysis of whole-cell lysates revealed that
chloroquine and dimethyl sulfoxide (D; used as a control) did not
block the ORF34-mediated degradation of HIF-1␣ (Fig. 6A, compare lane 1 to lanes 4 and 5), whereas treatment of cells with
MG132 restored the expression of HIF-1␣ in the presence of
ORF34 (Fig. 6A, lanes 1 and 3). We next examined the effects of
MG132 in cells cotransfected with degradation-resistant HIF-1␣
plasmid with ORF34. GFP34 was coexpressed with Flag-tagged
HIF-1␣w or HIF-1␣m expression plasmids and maintained in the
absence or presence of MG132. Immunoblot analysis revealed
that, in the absence of GFP34, MG132 increased the accumulation
of HIF-1␣ expression compared to that of untreated cells (Fig. 6B,
lanes 1 and 2). In the presence of GFP34, expression of HIF-1␣
was inhibited but treatment of cells with MG132 partially restored
the accumulation of HIF-1␣ expression (Fig. 6B, lanes 3 and 4). In
contrast, a steady expression level of HIF-1␣ was maintained in
cells cotransfected with a Flag-tagged HIF-1␣m plasmid regardless of MG132 treatment (Fig. 6B, lanes 5 and 6). Collectively,
these results suggest that the proteasomal degradation pathway is
involved in ORF34-mediated degradation of HIF-1␣ protein.
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HEK293 cells were cotransfected with expression plasmids encoding Flagtagged HIF-1␣ wild-type or mutant plasmids (600 ng) in the presence or
absence of GFP34 (300 ng) as indicated. The total amount of DNA in each well
was kept constant. Whole-cell extracts were prepared at 30 h posttransfection
and immunoblotted with anti-HIF-1␣ and anti-GFP antibodies to detect the
levels of their expression. (B) Cotransfection of ORF34 downregulates HIF-1␣
protein in a dose-dependent manner. HEK293 cells were cotransfected with a
fixed amount (600 ng) of Flag-tagged HIF-1␣w expression plasmid and with
increasing amounts (0 to 400 ng) of GFP34 plasmid. Whole-cell extracts were
prepared at 30 h posttransfection and immunoblotted with specific antibodies
as indicated to detect the levels of their expression.

To confirm that the HIF-1␣ degradation in ORF34-transfected
cells is mediated by cellular proteases, we used cycloheximide to
block new protein synthesis. Since our dose-response experiment
(Fig. 5B) revealed that as little as 100 ng of GFP34 can reduce the
expression of wild-type HIF-1␣ significantly, we used this lowest
dose of GFP34 to cotransfect HEK293 cells with 600 ng of Flagtagged HIF-1␣ wild-type or mutant plasmids in the presence or
absence of GFP34. After 24 h of transfection, cell lysates were
prepared at different time points after cycloheximide treatment.
An enhanced degradation of wild-type HIF-1␣ was observed in
cells transfected with GFP34 compared to cells transfected with
control vector (Fig. 6C). In contrast, the HIF-1␣ protein level
remained relatively constant in cells cotransfected with mutant
HIF-1␣ and GFP34 (Fig. 6C). These results indicate that ORF34
targets HIF-1␣ for proteasome-dependent degradation.
To confirm that ORF34 protein promotes the degradation of
HIF-1␣ through the ubiquitin pathway, we examined the ubiquitination state of HIF-1␣ by an in vivo ubiquitination assay. The
HA-ubiquitin expression plasmid was coexpressed with Flagtagged wild-type HIF-1␣ in the presence or absence of GFP34 in
HEK293 cells. After 30 h of transfection, cells were treated with
MG132 for 16 h before harvest. Cells were washed once in PBS and
lysed in 0.5% IGEPAL lysis buffer. Equal amounts of total cell
lysates (800 g) were immunoprecipitated with anti-Flag or
anti-HA antibody and then immunoblotted with anti-HA or antiFlag antibody to detect the ubiquitination level of HIF-1␣. In the
absence of GFP34, a higher level of ubiquitinated HIF-1␣ was
observed when the immunoprecipitates were probed with either
anti-HA or anti-Flag antibody. However, the level of ubiquiti-
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FIG 6 ORF34 protein induces degradation of HIF-1␣ via the proteasome pathway. (A) HEK293 cells were cotransfected with 600 ng of Flag-tagged HIF-1␣
wild-type plasmid along with 100 ng of GFP34 and control empty vector. After 30 h of transfection, cells were left untreated or were treated with specific inhibitors
of either the proteasomal (MG132; MG) or lysosomal (CQ) degradation pathway and harvested 16 h after treatment. Whole-cell extracts were prepared and
immunoblotted with specific antibodies. (B) HEK293 cells were cotransfected with 600 ng of Flag-tagged HIF-1␣ wild-type or mutant plasmids along with 300
ng of GFP34, and the total amount of DNA was kept constant with the control vector. After 30 h of transfection, MG132 or control DMSO was added to specific
wells and harvested after 16 h of treatment. Whole-cell extracts were prepared and immunoblotted with specific antibodies as indicated. An asterisk denotes
nonspecific binding by the antibody used. (C) ORF34 protein decreases the stability of wild-type HIF-1␣ protein. HEK293 cells were cotransfected with 600 ng
of Flag-tagged wild-type HIF-1␣ or mutant plasmid along with 100 ng of GFP34, and the total amount of DNA was kept constant with the control vector. After
24 h of transfection, cycloheximide was added for the indicated periods, and whole-cell lysates were prepared and immunoblotted with specific antibodies as
indicated.

nated HIF-1␣ appeared to be substantially reduced in cells
cotransfected in the presence of GFP34 (Fig. 7A, left and middle).
In contrast, when the cell lysates were immunoprecipitated with
anti-GFP antibody, the ubiquitination level of ORF34 remained
unaffected regardless of the presence of HIF-1␣ (Fig. 7A, right).
Immunoblotting of cell extracts with specific antibody revealed
that expression of GFP34 caused reduction in the overall levels of
ubiquitin as well as HIF-1␣, while the level of actin remained
unaffected (Fig. 7B).
DISCUSSION

We have previously shown that ORF34 is an early-late lytic gene
activated by hypoxia via a functional HRE sequence located within
the ORF34 promoter region. Hypoxia-induced transcriptional activation of ORF34 leads to transcriptional activation of the downstream genes ORF35 to ORF37 using the same HRE sequence (15,
16). In this study, we show that ORF34 downregulates HIF-1␣
protein levels and therefore HIF-1␣-dependent transcription.
This inhibitory activity apparently is due to direct binding of
ORF34 to HIF-1␣, leading to its degradation by the ubiquitindependent proteasome pathway. In this regard, ORF34 acts as a
feed-back inhibitor of HIF-1␣-dependent transcription.
Initial experiments in transfected cells revealed that expression
of ORF34 reduced HIF-1␣-dependent transcription of two prototypic HIF-␣-responsive promoters (VEGFp12 and pEpoE-Luc)
(45, 46, 48). In these experiments, HIF-1␣w and HIF-1␣m (hy-
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droxylation-resistant mutant) plasmids were utilized. HIF-1␣mmediated transcriptional activation of these promoters was inhibited by ORF34. This is the first report of a KSHV gene that appears
to downregulate HIF-1␣-dependent transcription. Coimmunoprecipitation assays revealed that ORF34 and HIF-1␣ physically
interacted. Apparently, this interaction requires the N-terminal
bHLH and PAS domains of HIF-1␣. Interestingly, this HIF-1␣
amino-terminal domain interacted with truncated versions representing the amino terminus, central region, and carboxyl terminus of the ORF34 protein, with the strongest interaction observed
with the ORF34 carboxyl terminus (GFP34 D3). The three ORF34
fragments that interact with HIF-1␣ do not appear to contain
repeat domains that could explain the observed binding. Therefore, these three domains appear to independently bind to HIF1␣, and as such it is likely that they represent linear-discontinuous
binding sites for different HIF-1␣ domains.
Examination of the stability of HIF-1␣ in the presence of
ORF34 revealed that HIF-1␣ was degraded in an ORF34 dosedependent manner. Apparently, HIF-1␣ degradation was enhanced in the presence of cycloheximide, indicating that HIF-1␣
degradation by ORF34 did not require de novo protein synthesis.
Therefore, the observed downregulation of HIF-1␣ transcription
was largely due to HIF-1␣ degradation after binding to ORF34
protein. Regulation of HIF-1␣ protein stability is critical in maintaining the function of HIF-1␣. HIF-1␣ undergoes rapid ubiquitination by binding to the von Hippel-Lindau (pVHL) protein
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FIG 7 Ubiquitination of HIF-1␣ and ORF34. (A) HEK293 cells were cotransfected with HA-tagged ubiquitin (HA-Ub; 300 ng) along with GFP-tagged ORF34
(100 ng) or Flag-tagged HIF-1␣w (600 ng) or with a combination of both as indicated. The total amount of DNA in each well was kept constant using a control
vector. After 30 h of transfection, cells were treated with MG132 for 16 h. Whole-cell extracts were prepared and immunoprecipitated with anti-Flag, anti-HA,
or anti-GFP antibody and analyzed by immunoblotting with specific antibody as indicated. (B) Expression of ubiquitin, HIF-1␣, and ORF34 in total cell extracts
was analyzed by immunoblotting with the indicated specific antibody. The asterisk in the middle panel denotes nonspecific binding by the antibody used.

complex followed by proteasomal degradation, resulting in inactive protein production (29, 36, 49–51). Hydroxylation of specific
proline residues of HIF-1␣ to alanine (P402A and P564A) prevents ubiquitination, leading to stable HIF-1␣ protein production. Stability and regulation of HIF-1␣ protein have been more
extensively studied with other cellular proteins. Recently, heat
shock protein 70 (HSP70) and carboxyl terminus of Hsc70-interacting protein (CHIP) were identified as the HIF-1␣ interacting
proteins and were shown to promote the ubiquitination and proteasomal degradation of HIF-1␣ (2). Initial evidence that HIF-1␣
stability is functionally linked to its ubiquitination status was obtained in experiments where the ubiquitin-proteasome pathway
inhibitor MG132 prevented HIF-1␣ degradation in the presence
of ORF34. HIF-1␣ appeared to be less ubiquitinated in the presence of ORF34. However, this reduction in ubiquitination is probably due to lower levels of HIF-1␣ due to ORF34-dependent degradation.
Interestingly, ORF34 protein appeared to be ubiquitinated in
transient expression assays; however, the presence of HIF-1␣ did
not affect the overall levels of ORF34 ubiquitination (Fig. 7). The
fact that ORF34 protein is not degraded in the presence of HIF-1␣
indicates that the ORF34-HIF-1␣ protein complex does not cause
degradation of both proteins. Therefore, these results suggest that
physical interaction of ubiquitinated ORF34 with HIF-1␣ leads to
HIF-1␣ degradation. Ubiquitination and proteasomal degradation of HIF-1␣ is mediated by the pVHL protein. Alignment of
pVHL amino acid sequence with that of ORF34 protein did not
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reveal any significant sequence similarities. It is not known
whether pVHL interacts with HIF-1␣ in the presence of ORF34.
Alternatively, it is possible that ORF34 uses a novel strategy to
regulate HIF-1␣ stability and ubiquitination independently of
pVHL. Further studies are needed to elucidate the mechanism by
which ORF34 regulates HIF-1␣ stability.
Other KHSV-encoded proteins have been found to physically
interact with HIF-1␣. The KSHV latency-associated nuclear antigen 1 (LANA1) was shown to physically interact with HIF-1␣
protein (13). Apparently, LANA1 stabilizes HIF-1␣, causing enhanced RTA expression in PEL cell lines expressing LANA1. The
KSHV viral interferon (IFN) regulatory factor 3 (vIRF3), known
as latency-associated nuclear antigen 2 (LANA2), also was shown
to interact with HIF-1␣ protein. In this instance, this interaction
increased HIF-1␣ stability and HIF-1␣-dependent transcriptional
activity (17). Furthermore, expression of vIRF3 led to increased
levels of VEGF expression and facilitated endothelial tube formation (17). Finally, the ORF74-encoded lytic protein, also known as
G protein-coupled receptor (vGPCR), was shown to upregulate
the expression of VEGF by stimulating the activity of HIF-1␣,
resulting in the activation of p38 mitogen-activated protein kinase
(18). Thus, both latent and lytic genes of KSHV interact with and
stabilize HIF-1␣, enhancing HIF-1␣-dependent transcriptional
activation. HIF-1␣ stability has been shown to be negatively regulated via a few cellular genes, including HSP70, CHIP, and spermidine/spermine N1-acetyltransferase-1 (SSAT-1) (2, 52). In all
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of these cases, these proteins bind to HIF-1␣, causing increased
HIF-1␣ ubiquitination and degradation (2, 52).
The results described here show, for the first time, that HIF-1␣
can be destabilized by the KSHV ORF34 protein. Collectively,
these results suggest that KSHV possesses multiple mechanisms
for tightly controlling HIF-1␣ transcriptional activity. Hypoxia
can induce lytic replication of KSHV in PEL cells. Apparently, the
KSHV latent protein LANA interacts with HIF-1␣ to upregulate
RTA expression and KSHV lytic replication during hypoxia (13).
Therefore, it is possible that ORF34 competes with LANA for
HIF-1␣ binding to inhibit KSHV lytic replication. This intricate
HIF-1␣ regulation may be crucial to control the lytic versus latent
status of KSHV within tumors.
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